SOPHiA GENETICS SA (NASDAQ:SOPH) Receives Consensus Recommendation of “Hold” from Analysts

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) have earned an average recommendation of “Hold” from the five analysts that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $9.00.

SOPH has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. HC Wainwright assumed coverage on shares of SOPHiA GENETICS in a research note on Monday. They set a “buy” rating and a $12.00 price target on the stock. Zacks Research raised shares of SOPHiA GENETICS to a “hold” rating in a report on Tuesday. Finally, BTIG Research restated a “buy” rating and issued a $8.00 price objective on shares of SOPHiA GENETICS in a research report on Monday, June 15th.

Insider Buying and Selling

In other news, insider Zhenyu Xu sold 7,393 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.17, for a total transaction of $38,221.81. Following the completion of the sale, the insider owned 614,887 shares in the company, valued at $3,178,965.79. The trade was a 1.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ross Muken sold 9,838 shares of the firm’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.22, for a total value of $51,354.36. Following the completion of the transaction, the chief executive officer owned 670,651 shares in the company, valued at approximately $3,500,798.22. This represents a 1.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 176,711 shares of company stock worth $959,913. 4.88% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On SOPHiA GENETICS

Several institutional investors have recently modified their holdings of the business. First Dallas Securities Inc. bought a new stake in shares of SOPHiA GENETICS during the first quarter worth approximately $50,000. Squarepoint Ops LLC acquired a new stake in SOPHiA GENETICS during the 3rd quarter worth $49,000. Perkins Capital Management Inc. acquired a new stake in SOPHiA GENETICS during the 4th quarter worth $49,000. Quadrature Capital Ltd bought a new stake in shares of SOPHiA GENETICS during the 4th quarter valued at $54,000. Finally, XTX Topco Ltd bought a new stake in shares of SOPHiA GENETICS during the 4th quarter valued at $55,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Key SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on SOPHiA GENETICS SA (NASDAQ: SOPH) and a $12 price target, signaling meaningful upside versus the current trading level. The firm’s model also forecasts the company moving toward profitability later in the decade.
• Positive Sentiment: The company’s CEO highlighted how AI could personalize patient therapies, reinforcing the growth narrative around SOPHiA GENETICS’ core technology and potentially supporting investor confidence in its long-term market opportunity. Article Title
• Neutral Sentiment: SOPHiA GENETICS said it will report second-quarter 2026 results on August 4. Upcoming earnings often keep a stock active, but this announcement is mainly a timing update rather than a business development. Article Title
• Neutral Sentiment: Zacks Research upgraded SOPHiA GENETICS to Hold, which is a small positive from a sentiment standpoint but not a strong enough signal to imply major near-term upside. Read More: Read More.
• Negative Sentiment: HC Wainwright’s estimates still show continued losses in 2026 and 2027, including full-year 2026 EPS of -$0.58 and full-year 2027 EPS of -$0.20. That highlights the company’s ongoing path-to-profitability risk, even with bullish long-term forecasts.

SOPHiA GENETICS Stock Performance

SOPHiA GENETICS stock opened at $6.40 on Thursday. The stock has a 50-day simple moving average of $5.34 and a 200 day simple moving average of $5.06. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05. SOPHiA GENETICS has a 12-month low of $2.92 and a 12-month high of $6.77. The stock has a market capitalization of $536.90 million, a price-to-earnings ratio of -12.31 and a beta of 0.96.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The company had revenue of $21.69 million for the quarter, compared to analyst estimates of $20.40 million. On average, research analysts anticipate that SOPHiA GENETICS will post -0.58 earnings per share for the current fiscal year.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.